Entity

Time filter

Source Type

San Diego, CA, United States

Patent
Harbor Therapeutics Inc. | Date: 2013-09-16

The invention relates to the use of compounds to ameliorate or treat an condition such as a cystic fibrosis, neutropenia or other exemplified conditions. Exemplary compounds that can be used include 3-hydroxy-17-aminoandrost-5-ene, 3-hydroxy-16-fluoro-17-aminoandrost-5-ene, 3-hydroxy-16-fluoro-17-aminoandrost-5-ene, 3-hydroxy-16-fluoro-17-aminoandrost-5-ene, 1,3-dihydroxy-4-fluoroandrost-5-ene-17-one, 1,3,17-trihydroxy-4-fluoroandrost-5-ene, 1,3-dihydroxy-6-bromoandrost-5-ene, 1-fluoro-3,12-dihydroxyandrost-5-ene-17-one, 1-fluoro-3,4-dihydroxyandrost-5-ene and 4-fluoro-3,6,17-trihydroxyandrostane.


Patent
Harbor Therapeutics Inc. | Date: 2013-06-17

The invention provides and describes solid state 17-ethynyl-5-androstane-3,17-diol including amorphous and crystalline forms and specific polymorphic forms thereof. Anhydrates and solvates of 17-ethynyl-5-androstane-3,17-diol include Form III anhydrate and Form I solvate. The invention further relates to solid and suspension formulations containing 17-ethynyl-5-androstane-3,17-diol in a described solid state form and use of the formulations to treat cancers or precancers such as prostate cancer or breast cancer in subjects or human patients. The invention also relates to methods to make liquid formulations from solid state forms of 17-ethynyl-5-androstane-3,17-diol and uses of such formulations in treating the described conditions.


Patent
Harbor Therapeutics Inc. | Date: 2012-08-01

The invention provides and describes solid state 17-ethynyl-androst-5-ene-3,7,17-triol including amorphous and crystalline forms and specific polymorphic forms thereof. Anhydrates and solvates of 17-ethynyl-androst-5-ene-3,7,17-triol include Form I anhydrate and Form IV and Form V solvates. The invention further relates to solid and suspension formulations containing 17-ethynyl-androst-5-ene-3,7,17-triol in a described solid state form and use of the formulations to treat hyperglycemic conditions, such as type 2 diabetes and metabolic syndrome, and autoimmune conditions, such as rheumatoid arthritis, ulcerative colitis and type 1 diabetes, among other inflammation related conditions in subjects or human patients. The invention also relates to methods to make liquid formulations from solid state forms of 17-ethynyl-androst-5-ene-3,7,17-triol and uses of such formulations in treating the described conditions.


Patent
Harbor Therapeutics Inc. | Date: 2014-08-14

The invention provides and describes solid state 17-ethynyl-androst-5-ene-3,7,17-triol including amorphous and crystalline forms and specific polymorphic forms thereof. Anhydrates and solvates of 17-ethynyl-androst-5-ene-3,7,17-triol include Form I anhydrate and Form IV and Form V solvates. The invention further relates to solid and suspension formulations containing 17-ethynyl-androst-5-ene-3,7,17-triol in a described solid state form and use of the formulations to treat hyperglycemic conditions, such as type 2 diabetes and metabolic syndrome, and autoimmune conditions, such as rheumatoid arthritis, ulcerative colitis and type 1 diabetes, among other inflammation related conditions in subjects or human patients. The invention also relates to methods to make liquid formulations from solid state forms of 17-ethynyl-androst-5-ene-3,7,17-triol and uses of such formulations in treating the described conditions.


Patent
Harbor Therapeutics Inc. | Date: 2013-06-17

The invention provides and describes solid state 17-ethynyl-5-androstane-3,17-diol including amorphous and crystalline forms and specific polymorphic forms thereof. Anhydrates and solvates of 17-ethynyl-5-androstane-3,17-diol include Form III anhydrate and Form I solvate. The invention further relates to solid and suspension formulations containing 17-ethynyl-5-androstane-3,17-diol in a described solid state form and use of the formulations to treat cancers or precancers such as prostate cancer or breast cancer in subjects or human patients. The invention also relates to methods to make liquid formulations from solid state forms of 17-ethynyl-5-androstane-3,17-diol and uses of such formulations in treating the described conditions.

Discover hidden collaborations